CEbiotech.com - Central European Biotechnology Portal
be visible on the BioBusiness market                  ISSN 2300-0228
Most popular
searches

All articles

Filters:
Show search box
2013-11-18 to 2015-11-16
Movember – about a microbiome in (prostate) cancer risk

Movember – about a microbiome in (prostate) cancer risk

10 years ago a Nobel Prize awarded a discovery connecting Helycobacter pylori with gastric carcinogenesis. But only today, a host-microbiome relation research starts to enter its critical phase. It turns out, that we are not the only architects of our own fortune – they are, small frequenters of our ... Read more
Tags cancer , movember , prostate cancer , microbiome , microflora , cancer risk , holobiont
Immatics and Roche sign cancer vaccine and immunotherapy collaboration

Immatics and Roche sign cancer vaccine and immunotherapy collaboration

Collaboration spans the discovery, development and commercialization of cancer vaccines and other cancer immunotherapies in gastric, lung and prostate cancer ... Read more
Tags cancer , Roche , Immatics , collaboration , partnership
2015-09-09
IASOcholine radiotracer export to the Czech Republic and Slovakia

IASOcholine radiotracer export to the Czech Republic and Slovakia

Synektik Group - a leading provider of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine - begins delivery of a special radiotracer, IASOcholine, to the Czech Republic and Slovakia. PET-CT imaging using Choline radiotracer is one of the most modern methods use... Read more
Tags cancer , radiopharmaceuticals , diagnostics
2015-03-25
Green light for Novartis drug “Jakavi” for rare blood cancer treatment

Green light for Novartis drug “Jakavi” for rare blood cancer treatment

Novartis drug “Jakavi” has been approved by the European Commission for the therapy of rare blood cancer, polycythemia vera. It is the first approved targeted drug for treatment of this disease and it gives hope for patients unresponsive to standard therapy with hydroxyurea.... Read more
Tags drug , cancer , eu , Novartis , targeted therapy , approval
2015-02-04
Wortmannin as a new potential anticancer drug

Wortmannin as a new potential anticancer drug

Wortmannin sensitize the tumour cells for standard treatment with ethoposid and cisplatin, makes the treatment more effectiveness. What it means for the glioma patient? That there is potential new drug, which is effective in laboratory and kills glioma cells.... Read more
Tags cancer , glioblastoma , glioma , oncology , brain cancer
2015-01-28
How cancer cells can interact with each other?

How cancer cells can interact with each other?

Interactions between cells are of crucial importance for the proper functioning of tissues and the whole multicellular organisms. During pathological processes, such as cancer progression, alterations in cell-cell adhesion are very common. The molecular events underlying these changes must be deeply ... Read more
Tags junction , Jonas Fuxe , epithelium , interaction , cancer
2014-12-31
Life science sector in the next 15 years

Life science sector in the next 15 years

Life science sector comprising such areas as biotechnology, pharmacy or biomedical technologies is one of the most rapidly growing markets. As societies all over the world are getting older and older, we can be sure that in the nearest 15 years its development will be even faster than nowadays.... Read more
Tags cancer , life science , future , ageing , Alexander Stratz
2014-12-22
Understanding angiogenesis process is crucial for modern medicine

Understanding angiogenesis process is crucial for modern medicine

Angiogenesis, comprising a growth of blood vessels, is indispensable for proper organ functioning and repair. Abnormalities occurring in this crucial process are involved in various disorders such as cancer. Understanding its molecular background is the basis for the development of novel efficient dr... Read more
Tags medicine , cancer , angiogenesis , Yihai Cao , blood vessel , metabolism , obesity
2014-12-05
Nucleolin as a target for anti-cancer therapy

Nucleolin as a target for anti-cancer therapy

Nucleolin, a multifunctional phosphoprotein present mainly in nucleolus, has drawn much attention of molecular biologists due to its role in carcinogenesis and potential of being attractive target for more efficient therapies. As current methods of cancer treatment are still highly unspecific, such a... Read more
Tags nucleolin , cancer , antibody , Bradford Goodwin , therapy
2014-08-27
Avastin – chance in cancer treatment

Avastin – chance in cancer treatment

European Commission (EC) approved the bevacizumab (Avastin) as a medication in treating recurrent ovarian cancer resistant to chemotherapy containing platinum. Avastin has to be combined with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy.... Read more
Tags cancer , Avastin , cancer therapy , ovarian cancer
2014-08-19
Toxoplasma gondii seems to be helpful in cancer treatment

Toxoplasma gondii seems to be helpful in cancer treatment

Common cat parasite which is harmful and sometimes deadly to people can be transformed into anticancer vaccine. Tumors disturbed natural immune response in order to be safe against natural forces defense of the body. While T. gondii is presence in cells, they started to produce toxic lymphocytes T an... Read more
Tags anticancer treatment , parasite , therapeutic vaccine , immune response , immunology , cat , cancer , T. gondii
2014-06-24
Green tea – a remedy for cancer?

Green tea – a remedy for cancer?

One of the most commonly worldwide consumed beverages is tea. Still black tea is consumed most frequently, however, the green tea contains majority of natural bio-active chemicals beneficial for our health. Epigallocatechin-3-gallate (EGCG) is an active compound of green tea that was used in studies ... Read more
Tags medicine , cancer , green tea , pancreas
2013-11-12
Vintafolide - a chance for Platinum-Resistant Ovarian Cancer treatment.

Vintafolide - a chance for Platinum-Resistant Ovarian Cancer treatment.

Merck, one of the leaders in production of pharmaceuticals, put its new medicine under review. It is called vintafolide, MK-8109 and it is an injectable drug conjugate consisting of folate (vitamin B9) linked to alkaloid chemotherapy agent, desacetylvinblastine monohydrazine (DAVLBH). ... Read more
Tags medicine , cancer , Merck , MSD , cancer targetting
2013-11-04
FDA approves Gazyva – a new treatment of chronic lymphocytic leukaemia

FDA approves Gazyva – a new treatment of chronic lymphocytic leukaemia

On 1 November 2013, Genentech announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) to be used with chlorambucil chemotherapy for the treatment of chronic lymphocytic leukemia (CLL). ... Read more
Tags cancer , leukemia , CLL , antibody , Genentech , Roche , chemoterapy
Merck Serono and Selvita Announce Research Collaboration in Cancer

Merck Serono and Selvita Announce Research Collaboration in Cancer

Darmstadt, Germany, October 24, 2013 – Merck Serono, the biopharmaceutical division of Merck, and Selvita, a biotechnology company based in Poland, announced today that they have entered into a collaboration to jointly discover small molecule based drugs targeting proteins involved in cancer cell met... Read more
Tags poland , cancer , Selvita , Merck , Serono , Collaboration
2013-05-28
Cancer and senescence.

Cancer and senescence.

Cancer experts from Denmark have found an enzyme that seems to induce cancer senescence.... Read more
Tags medicine , cancer
2013-05-08
Cancer less cancerous?

Cancer less cancerous?

Researchers at Johns Hopkins University have identified a gene which repressed in tumor cells, puts a halt to cell growth and a range of processes needed for tubers to enlarge and spread to distant sites. The researchers hope that this so-called "master regulator” gene may be the key to develop a new... Read more
Tags medicine , cancer